HLA-C and neoplasm: In contrast, BEVs address these challenges through (1) Scalability—Gram‐negative bacterial cultures enable high‐yield production (50–200 μg/mL) using cost‐effective fermentation techniques29; (2) Safety—BEVs lack endogenous mammalian surface markers (e.g., MHC complexes), minimizing immune clearance and off‐target interactions30; and (3) Engineerability—The modular structure of BEVs permits reliable functionalization, as demonstrated by our LCTP ligand conjugation (NNPWREMMYIEI)40 for tumor‐targeted delivery.